Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Eur Urol. 2016 May 6;70(6):963–970. doi: 10.1016/j.eururo.2016.04.023

Table 3.

Treatment-emergent adverse events occurring in ≥15% of patients

High-risk nmCRPC (n = 51)
All grades Grade ≥3*
No. of patients with ≥1 TEAE 51 (100) 21 (41)
No. of patients with a serious TEAE 16 (31) 12 (24)
TEAEs, n (%) All grades Grade ≥3*
Fatigue 31 (61)   2 (4)
Diarrhea 22 (43)   1 (2)
Nausea 20 (39)   0
Arthralgia 11 (22)   1 (2)
Back pain 11 (22)   0
Dysgeusia 11 (22)   0
Hypothyroidism 11 (22)   0
Hot flush 10 (20)   0
Pain in extremity 10 (20)   1 (2)
Cough 10 (20)   0
Abdominal pain   9 (18)   0
Decreased weight   9 (18)   0
Pollakiuria   9 (18)   0
Constipation   8 (16)   0
Nasopharyngitis   8 (16)   0
Hematuria   8 (16)   0
Upper respiratory infection   8 (16)   0

nmCRPC = nonmetastatic castration-resistant prostate cancer; TEAE = treatment-emergent adverse event.

*

Listed grade ≥3 adverse events are those with an overall incidence ≥15%.